Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
Drug guidance

Pembrolizumab for treating persistent, recurrent, or metastatic cervical cancer

Condition

Cancer

Gynaecological

1 August 2025

Published on 02 Jan 2024
Last Updated on 01 Aug 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended pembrolizumab for inclusion on the MOH List of Subsidised Drugs, when used in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent, or metastatic cervical cancer in patients whose tumours express programmed death-ligand 1 with a combined positive score greater than or equal to 1. The decision was based on the uncertain extent of clinical benefit and unfavourable cost-effectiveness of pembrolizumab at the price proposed by the company.

Clinical indications, subsidy class and MediShield Life claim limit for pembrolizumab are provided in the Annex.

Pembrolizumab for treating persistent, recurrent, or metastatic cervical cancer (Updated 1 Aug 2025) [PDF, 303 KB]

PES Pembrolizumab for treating advanced cervical cancer (Published 2 Jan 2024) [PDF, 85 KB]

Back to top